“With an existing licensing agreement, the company is also well on its way to commercialization after spending more than a decade fine-tuning its technology–and developing products that have applications across an array of industries.” The article states.
The article describes the issue of bioavailability a major problem facing the medical cannabis industry.
It further talks about the company’s patent-pending delivery system which he absorption issues associated with a wide variety of products.
“NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) represents a compelling investment opportunity in the legal cannabis industry.”, concludes the article.
To read the full article click here